In top-line results from a Phase IIa study, Abivax has reported mixed data, although ABX464 did appear to reduce HIV DNA in blood and rectal samples at a higher dose.
Research presented at ASM Microbe has revealed that Treg cells may be protecting babies from contracting HIV from their mothers in utero.
The US FDA and the European Medicines Agency are investigating reports of neural tube defects in babies born to women on GlaxoSmithKline’s antiretroviral drug dolutegravir.
A new study has highlighted the neurological damage caused by exposure to HIV without antiretroviral therapy.
Two genetically-modified broadly-neutralizing antibodies have been demonstrated to elicit long-term protection against an HIV-like virus in rhesus macaques, with a Phase I clinical trial now underway.
New research has suggested that a protein involved in Alzheimer’s disease may also be implicated in HIV-associated neurological disorders, suggesting Alzheimer’s therapies may benefit a subset of HIV patients.
Mylan N.V have announced they’ll be launching their third HIV combination in the US, following FDA approval of their once-daily treatment Symfi™.
TB and HIV are two intertwined infective challenges for global health and therefore they need to be addressed with an integrated approach.
For International Women’s Day, we spoke to Sharon Lewin about her typical day, who inspires her and her great deal of international travel!
With the microbiome becoming a much talked about topic in recent years, we spoke to Sergio Serrano-Villar, author of Future Microbiology’s top-read article of 2017 entitled: ‘How can the gut microbiota affect immune recovery in HIV infected individuals?’.